Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
MedTech
RadNet to absorb mammography AI developer iCad in $103M deal
The all-stock transaction is valued at about $103 million, or a 98% premium over iCad’s recent share price.
Conor Hale
Apr 16, 2025 2:05pm
Relay starts 3rd layoff wave in one year, shedding 70 staffers
Apr 4, 2025 11:30am
Pfizer, Arvinas' PROTAC posts mixed results in first ph. 3 test
Mar 11, 2025 10:06am
AstraZeneca’s oral SERD hits goal in phase 3 breast cancer trial
Feb 26, 2025 5:40am
Roche companion test moves into HER2-ultralow breast cancer
Feb 4, 2025 12:00pm
Lilly inks $2.5B Scorpion buyout in twist to breast cancer tale
Jan 13, 2025 9:55am
